MedTrace Logo

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

NCT01311258 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-09-17

No results posted yet for this study

Summary

This study is being performed to develop assays to determine the impact of the therapy patients receive for treatment of AML or MDS and to determine if these tests can identify those patients who are at a greater risk for having their disease relapse.

Conditions

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Michael W Becker, MD · University of Rochester

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2030-08-31
Completion
2030-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01311258 on ClinicalTrials.gov